Needham Names Five Top Biotech Picks for H2 2026 on Clinical Catalysts

Investment firm Needham & Company has highlighted five biotechnology stocks as its top picks for the second half of 2026, anticipating significant momentum from key clinical and commercial catalysts. In a research note, the firm reiterated its Buy ratings for all five companies, which are focused on developing treatments for neurological, psychiatric, and rare diseases.

Catalysts on the Horizon

Needham's selections are heavily influenced by upcoming data readouts from late-stage clinical trials, which represent major potential inflection points for the companies. The firm outlined specific events investors are watching for in the coming months.

Key picks and their near-term catalysts include:

• Praxia Therapeutics (PRAX): With a price target of $582, the company is expected to release Phase 3 EMERALD study data for its epilepsy treatment, relutrigine, in the second half of the year.
• Acadia Pharmaceuticals (ACAD): Needham set a $41 price target, citing the upcoming Phase 2 RADIANT data for remlifanserin in Alzheimer’s disease psychosis, expected in September or October. The firm assigns a 70% likelihood that the study will meet its primary endpoint.
• Biogen (BIIB): The firm's $256 price target is supported by an upcoming slate of eight Phase 3 readouts through 2029. The next major update is data for Litifilimab in systemic lupus erythematosus (SLE), anticipated in the fourth quarter of 2026.
• Axsome Therapeutics (AXSM): A price target of $268 is backed by the strong commercial launch of its depression drug Auvelity and upcoming Phase 3 ENGAGE study data for solriamfetol in binge eating disorder.
• Alkermes (ALKS): Needham is optimistic about the company's orexin franchise, setting a $62 price target ahead of Phase 1b data for ALKS-7290, expected by the end of the third quarter of 2026.

Ad

Investor and Market Implications

These selections underscore the event-driven nature of the biotechnology sector, where the outcome of clinical trials can significantly impact a company's valuation. Positive results can unlock substantial value and pave the way for regulatory submissions, while trial failures often lead to sharp stock declines.

Several of Needham's picks have already seen strong performance, with Axsome up 21% and Alkermes up 68% year-to-date, according to the source. The firm's analysis suggests that the upcoming data readouts could provide further upside, offsetting broader market trends and rewarding investors focused on fundamental pipeline developments.